Natera, Inc. - NTRA STOCK NEWS

Natera (NASDAQ: NTRA) announced three new peer-reviewed publications for its Signatera test, surpassing 85 total publications. Key highlights include:

1. Colorectal cancer (CRC) data from the GALAXY arm of CIRCULATE-Japan, published in Nature Medicine and presented at ESMO 2024, showing Signatera's ability to predict overall survival and adjuvant chemotherapy benefit.

2. Additional CRC data from GALAXY, published in Annals of Oncology, demonstrating Signatera's ability to risk-stratify patients after liver metastases resection.

3. Breast cancer data from the BELLINI trial, published in Nature Medicine, exploring immune checkpoint inhibitors without chemotherapy in triple-negative breast cancer, with Signatera showing correlation to treatment response.

Natera, Inc. (NASDAQ: NTRA) announced new data from the GALAXY arm of the CIRCULATE-Japan trial at the 2024 ESMO Congress. The study, involving 2,240 patients with stage II-IV colorectal cancer, demonstrated Signatera's ability to predict overall survival (OS) and adjuvant chemotherapy (ACT) benefit. Key findings include:

1. Signatera-positive patients showed 9.68 times higher risk of death compared to Signatera-negative patients.

2. Signatera-positive patients receiving ACT had a 50% reduction in death risk.

3. Signatera status was the most significant predictor of recurrence across all pathologic stages.

4. Sustained Signatera clearance after ACT was associated with 100% 24-month OS.

These results highlight Signatera's potential to improve outcomes for colorectal cancer patients through personalized treatment decisions.

Natera will present new data on its Signatera molecular residual disease (MRD) test at the 2024 ESMO Congress. Key highlights include:

1. Data from the GALAXY arm of CIRCULATE-Japan trial, showing Signatera-positive patients had significantly shorter overall survival (OS) compared to Signatera-negative patients (hazard ratio ~10).

2. First prospective read-out of OS based on MRD in colorectal cancer (CRC).

3. New data on adjuvant chemotherapy (ACT) benefit in Signatera-positive and negative patients.

4. Additional presentations on Signatera in breast cancer and squamous cell carcinoma of the head and neck.

These findings underscore Signatera's potential to predict long-term outcomes and guide treatment decisions in early-stage CRC.

Natera, a leader in cell-free DNA and genetic testing, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Wednesday, Sept. 4 at 2:35 pm ET | 11:35 am PT in New York City. Natera's leadership team will be presenting at the conference.

Investors and interested parties can access a live webcast and audio archive of the presentation through the investor relations section of Natera's website at investor.natera.com. A replay of the event will be made available shortly after the conference concludes.

This participation highlights Natera's commitment to engaging with the investment community and showcasing its advancements in the field of genetic testing.

Natera (NASDAQ: NTRA), a leader in cell-free DNA and genetic testing, reported its Q2 2024 financial results.

Key highlights include total revenues of $413.4M, up 58.1% YoY, and product revenues of $411.4M, up 59.3%. Gross margin improved to 58.8% from 45.2%. The company processed approximately 760,300 tests, a 23.2% increase, including 125,400 oncology tests, a 50.2% increase. Natera achieved a positive cash flow of $3.3M.

Operating expenses rose to $287.1M, driven by headcount growth and increased consulting and legal costs. Net loss narrowed to $37.5M ($0.30/share) from $110.8M ($0.97/share) YoY. Natera's financial outlook for 2024 expects revenues between $1.49B and $1.52B, with a gross margin of 54%-56%.

The company launched a new feature for ProsperaTM Heart and presented new data at the ASCO 2024 Annual Meeting.

Natera, a leader in cell-free DNA testing, announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's leadership team will present on Wednesday, August 14 at 12:30 PM ET in Boston, MA. Investors and interested parties can access a live webcast of the event through Natera's investor relations website. For those unable to attend, a replay will be available shortly after the conference concludes.

This presentation offers an opportunity for investors to gain insights into Natera's current operations, future strategies, and potential growth prospects. As a key player in the cell-free DNA testing market, Natera's participation in this growth-focused conference may signal important developments or expansion plans for the company.

Natera (NASDAQ: NTRA), a leader in cell-free DNA testing, has announced it will release its second quarter 2024 financial results on August 8, 2024, after market close. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results.

Interested parties can access the conference call via the following dial-in numbers:

• Domestic: 1-888-596-4144
• International: 1-646-968-2525
• Conference ID: 7684785

A webcast of the call will be available at https://events.q4inc.com/attendee/455235752, with a replay accessible later at investor.natera.com.

Natera, Inc. (NASDAQ: NTRA) has announced a new study published in the Journal of Clinical Oncology highlighting the utility of its Signatera test for surveillance in Merkel cell carcinoma (MCC). The prospective, multicenter study included 319 patients with stage I-IV MCC. Key findings show that Signatera demonstrated:

- Approximately 95% sensitivity for detecting clinically evident disease at enrollment
- Up to 20 times higher risk of recurrence in ctDNA-positive patients during surveillance
- 91% recurrence-free probability at 12 months for persistently ctDNA-negative patients

The study suggests that Signatera could become a standard monitoring tool in MCC, potentially reducing the frequency of surveillance imaging and guiding treatment decisions.

Natera (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, will present its latest research and data at the 28th International Conference on Prenatal Diagnosis and Therapy. The event, hosted by the International Society of Prenatal Diagnosis (ISPD), will take place from July 7-10, 2024, in Boston, MA. Key presentations include:

1. The evaluation of discordant sex between SNP-based NIPT and prenatal ultrasound related to congenital lipoid adrenal hyperplasia (Presenter: India Bradley, MS, CGC, July 8, 3:30 PM ET).

2. Insights from preimplantation genetic testing on chromosome segregation of human non-homologous Robertsonian translocations (Presenter: Peter Benn, DSc, July 8, 3:30 PM ET).

3. The accuracy of fetal fraction measurement in non-invasive prenatal screening for fetal aneuploidy using SNP-based methodology (Presenter: Peter Benn, DSc, July 9, 10:15 AM ET).

Natera will also host an Industry Symposium on July 9, 2024, at 1:00 PM ET, focusing on the future of non-invasive prenatal testing (NIPT), featuring Medical Directors Samantha Leonard, MBBS, PhD, and Vivienne Souter, MD, MPH.

Sheetal Parmar, Natera's senior vice president of medical affairs for women's health, emphasized the significance of SNP-based NIPT and the company's contributions to preimplantation genetic testing.